|Bid||62.30 x N/A|
|Ask||62.31 x N/A|
|Day's Range||61.20 - 62.52|
|52 Week Range||61.20 - 178.87|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||24.31|
|Earnings Date||Apr. 12, 2022 - Apr. 18, 2022|
|Forward Dividend & Yield||0.40 (0.61%)|
|Ex-Dividend Date||May 21, 2021|
|1y Target Est||N/A|
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to improve the management of type 2 diabetes mellitus. The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects such as the stimulatio
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic. The two studies were conducted separately in subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567).
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes (EASD) Meeting. The meeting will be held virtually from September 27th – October 1st, 2021.